Tait Shanafelt, Mark C. Lanasa, Timothy G. Call, Anne W. Beaven, Jose F. Leis, Betsy LaPlant, Deborah Bowen, Michael Conte, Diane F. Jelinek, Curtis A. Hanson, Neil E. Kay and Clive S. Zent Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL) Cancer 119
Version of Record online: 6 AUG 2013 | DOI: 10.1002/cncr.28292
Ofatumumab-based chemoimmunotherapy (CIT) is well tolerated in patients with previously untreated chronic lymphocytic leukemia. The efficacy of ofatumumab-based CIT compares favorably to historical trials of rituximab-based CIT.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field